Originally Broadcast: Tuesday 9th March 2021 13.30 - 14.30 GMT
Duration: 90 minutes. Available to watch on demand
Understand the opportunities and challenges of cross border healthcare
Learn about the perspective and experiences of companies, payers & the European Commission
Understand the legal background to obtain reimbursement for a treatment in other EU countries
What is the right point in time to get in contact and whom to approach?
To what extent are national HTAs / submissions needed?
Have there been experiences with orphan drugs and cell and gene therapies?
Understand potential pathways in the EU 4 countries and in the UK
What are the timelines and procedures needed under the S2 (social security) pathway?
Who would benefit from registering to attend this webinar:
This webinar should be attended by those interested in cell and gene therapies and orphan medicines and how they can remove obstacles to patient access. This is aimed at BioPharma and MedTech companies as well as patient organisations and patient groups.
The job functions that will benefit most include:
• Heads of Market Access
• Managing Directors
• Country Managers
• Chief Executives
• Health Economists
• Medical Directors
• Commercial Directors
• Policy Officers/Executives
• Marketing Directors
• Policy Advisors
Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and works as a lawyer in the healthcare boutique law firm NOVACOS in Düsseldorf (www.novacos-law.com). He advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective.
From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie eV (BPI). Before, he has been a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Dr. Natz has also worked in the field of competition law with the European Commission and in the pharmaceutical industry.
Christian is a seasoned Market Access professional with over 20 years of experience in the International Biotech and Pharmaceutical industry. He has been involved in over 50 HTAs across Europe and has built up a strong network of key influencers including EU and national agencies. Prior to co-founding MAP in 2012, he led market access teams and submissions at InterMune, Gilead, Pfizer and Genzyme on a very broad range of products and disease areas from chronic disease to ultra-orphan indications.
Christian is a member of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepreneurs); he is also a member of the Steering Group of EMIG (Ethical Medicines Industry Group) in the UK and Ireland.
Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.
MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281
VAT Group Registration Number:
GB 292 8576 52